Drugs / Trimethoprim/Sulfamethoxazole
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03228108 | Apr 2018 → Sep 2021 | infectious disease, prostate cancer | Radboud University Medical Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trimethoprim/Sulfamethoxazole | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03228108 ↗ |
| Route | Oral | “trimethoprim/sulfamethoxazole (SXT) 960 mg orally 2 hours before and 12 hours after prostate biopsy” NCT03228108 ↗ |